^{The Augustine Therapeutics pipeline is based on a novel generation of small molecule inhibitors of HDAC6, a validated molecular target with strong biological rational for neuromuscular and neurodegenerative disorders, and high therapeutic potential in other cardiometabolism, inflammatory and autoimmune diseases.} 

We currently have three programs in development.

Our most advanced asset is at the regulatory non clinical developement stage. AGT100216 is the first clinical candidate, acting as a peripherally-restricted, orally bioavailable and selective HDAC6i for the treatment of Charcot-Marie-Tooth (CMT) disease with therapeutic application in other type of axonopathies such as Chemotherapy-induced peripheral neuropathy (CIPN). 

Our second program is a novel class of peripherally-restricted, orally bioavailable and selective HDAC6i for the treatment of cardio-metabolism diseases, currently in advanced lead optimization stage. 

Our third program is a focusing on brain penetrant, orally bioavailable and selective HDAC6i,  currently in lead optimization stage, for the treatment of neurodegenerative diseases, such as Amyotrophic lateral sclerosis or Frontotemporal dementia.

With a "Pipeline-in-a-product" approach, our drug discovery engine is poised to deliver multiple drug candidates with peripheral and central actions.